The number of drug launches in Europe has fallen by around 35% in the 10 months since the USA introduced a new drug pricing policy, according to an analysis by the international research agency GlobalData. The figures are serious for European patients, states the Danish pharma trade group Lif.
This article is accessible to registered applyrs, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered applyr please login. If your trial has come to an conclude, you can subscribe here.
Try before you acquire
Free
7 day trial access
- All the news that relocates the requiredle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to indusattempt-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely applyful and valuable Life Sciences service that brings toreceiveher a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Leave a Reply